Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMBL Ventures Snags $55 Million In First Closing For New European VC Fund

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite an ongoing European financial crisis, Germany's EMBL Ventures collects $55 million for its next venture fund to invest in European biotech.

You may also be interested in...



Euro Crisis Hits Investor Risk Appetite, But Opportunities Remain

There are good-value opportunities in Europe for VCs with money to invest, but those seeking new funds face an unprecedentedly tough challenge that’s compounded by euro uncertainty.

Prime Minister Cameron Plans To Boost U.K. Biotech With New "Catalyst" Fund, Early Patient Access Scheme

The U.K. plans to boost its life sciences sector with a series of measures, including a fund to support early-stage research and allowing early access to innovative medicines before regulatory approval.

UK Innovation Investment Fund: Are The Right Managers On The Job?

An effort to close the venture funding gap with the U.S. gets potential help in several ways.

Topics

Related Companies

UsernamePublicRestriction

Register

PS073137

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel